Grail spinoff- the largest AI Machine Learning Project in Medicine- Galleri is “The Holy Grail” of Genomic Testing
Grail is hard to analyze, but the potential upside is staggering. Due to their regulatory challenges, there is a paucity of information, obfuscated by likely insider dealing and related third-party transactions, and an abundance of lawyers due to regulatory challenges. Icahn waged a proxy fight, and ultimately, the EU forced Illumina to divest Grail. Analysts are probably waiting until the spin-off is done on June 24th before there will be much commentary, as many banks have been feeding at this trough . But first, here are some quick facts about the spinoff itself. https://www.sec.gov/Archives/edgar/data/1699031/000119312524148672/d556103dex991.htm#toc556103_ Grail will only have slightly over … Read more